IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023

2 years ago

LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

Smart for Life Enters into New Distribution Agreement with BOXOUT®, to Expand Distribution of Greens First Product Line

2 years ago

Launches New E-commerce Initiatives with BoxoutMIAMI, March 23, 2023 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for…

Healthcare Triangle to Participate in ViVE 2023 as Presenter and Sponsor

2 years ago

Company to host a “Tech Talk” featuring client CalvertHealth on March 27thPLEASANTON, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Healthcare…

Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time

2 years ago

BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

2 years ago

Commonly Used Pressure Measure for Volume Assessment Discordant with Direct Measurement by BVA Oak Ridge, TN, March 23, 2023 (GLOBE…

Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

2 years ago

– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing…

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

2 years ago

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with…

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

2 years ago

On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and…

Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET

2 years ago

REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated…